|
Published by: Kalorama Information
Published: Oct. 1, 2009 - 250 Pages
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
Scope and Methodology
- Total Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
- Overview
- Introduction to Pathogens
- Demographics of the World
- Anti-Infective Drug Resistance
- Antibiotic Abuse
- Antibiotic Use in Agriculture
- Resistance in Select Populations
- Children
- The Elderly
- Compromised Individuals
- Measures for Reducing Resistance
- Antibiotic Cycling
- Antibiotic Education
- Screening Hospitalized patients
- HIV Trends
- Infection Rates
- HIV and Women
- Costs and Funding of HIV Treatment
- Access to HIV/AIDS Treatment
- Manufacturer and Marketer Trends
- Trends in Partnerships and Alliances
- Developers Trends
- Trends in Rx-to-OTC Switches
CHAPTER THREE: ANTIFUNGAL DRUGS
- Overview
- Types of Fungal Infections
- Superficial
- Systemic
- Histoplasmosis
- Coccidioidomycosis
- Blastomycosis
- Fungal Infection Statistics
- Fungal Infection Risk
- Description of Antifungal Products
- Systemic Antifungals
- Allylamines
- Azoles
- Polyene Macrolides
Systemic Miscellaneous Antifungals- Topical Antifungals
Allylamines
Topical Azoles- Topical Polyene Macrolides
Topical Miscellaneous Antifungals
- Market Overview
- Total Market Size and Forecast
Antifungal Market by Product Type
- Allylamines
Azoles
Polyene Macrolides
Other Antifungals
Antifungal Market by Geographical Region
Market Analysis by Treated Condition
- Competitive Analysis
CHAPTER FOUR: ANTIBACTERIAL DRUGS
- Overview
- Classification of Antibacterial Organisms
Antimicrobial Spectrum
Bacterial Resistance
Principles of Anti-bacterial Therapy
- Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmacokinetics
Monitoring Therapy
- Combination Therapy and Prophylactic Use
Bacterial Infection Statistics
Bacterial Infection Risk
Description of Antibacterial Products
- Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Carbopenems
Systemic Miscellaneous Antibiotics
Market Overview
Total Market Size and Forecast
Antibacterial Market by Product Type
Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Carbopenems
Other Products
Antibacterial Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products
CHAPTER FIVE: ANTIVIRAL DRUGS
- Overview: Introduction to Viruses
Examples of Pathogenic Viruses
Virus Function and Life History
Replication in DNA Viruses
Replication of RNA Viruses
Replication in Retroviruses
Host Defenses Against Viruses
Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
Subversion of the Immune Response
Avoidance of Immune Detection and Attack by Killer Cells
- HIV and AIDS
- Viral Infection Statistics
Description of Antivirals Products
- Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Combination Nucleoside Reverse Transcriptase Inhibitors
Nucleotide Analogue Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Combination Non-Nucleoside Reverse Transcriptase Inhibitors
DNA Polymerase Inhibitors
Protease Inhibitors
Other Antivirals
Market Overview
Total Market Size and Forecast
- Antiviral Market by Product Type
Nucleoside Analogs
Protease Inhibitors
Other Antivirals
Antiviral Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
- Leading Products
CHAPTER SIX: MARKET SUMMARY
- Total Market Size and Forecast
Market by Segment
CHAPTER SEVEN: CORPORATE PROFILES
- Introduction
-
Abbott Laboratories
AstraZeneca/MedImmune
Bayer Schering Pharma AG -
Bristol-Myers Squibb
Daiichi Sankyo
Gilead Sciences
GlaxoSmithKline -
Johnson & Johnson Group
Merck & Co.
Novartis
Pfizer
Roche
Schering-Plough Corporation
Wyeth
APPENDIX: LIST OF MAJOR PROVIDERS
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2006-2013
- Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2009
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
- Table 2-1: Estimated World Population by Age and Geographical Region, 2009
- Figure 2-1: Estimated World Population by Age and Geographical Region, 2009
- Table 2-2: Worldwide HIV/AIDS Infections
- Table 2-3: Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent)
- Table 2-4: AIDS Resource Needs (US$ billion), 2006-2008
- Table 2-5: Antiretroviral Access for HIV Infected Individuals by Region, 2005*
- Table 2-6: Anti-Infective Drugs in Development by Developer
- Table 2-7: Anti-infectives Ingredients Transferred from Rx-to-OTC
CHAPTER THREE: ANTIFUNGAL DRUGS
- Table 3-1: Estimated World and U.S. Incidence of Fungal Infections
- Figure 3-1: Estimated World and U.S. Incidence of Leading Fungal Infections
- Table 3-2: World Population at Risk for Fungal Infections, Secondary to
Chronic Diseases by Selected Geographical Region, 2008-2009
- Figure 3-2: World Population at Risk for Fungal Infections, Secondary to
Chronic Diseases by Selected Geographical Region, 2008-2009
- Table 3-3: Systemic Allylamines
- Table 3-4: Systemic Azoles
- Table 3-5: Systemic Polyene Macrolides
- Table 3-6: Systemic Miscellaneous Antifungals
- Table 3-7: Topical Allylamines
- Table 3-8: Topical Azoles
- Table 3-9: Topical Polyene Macrolides
- Table 3-10: Topical Miscellaneous Antifungals
- Table 3-11: The World Market for Antifungal Drugs 2006-2013
- Figure 3-3: The World Market for Antifungal Drugs 2006-2013
- Table 3-12: Antifungal Drug Market by Type 2006-2013
- Figure 3-4: The World Market for Antifungal Drugs Revenues by
Type 2006-2013
- Figure 3-5: The World Market for Antifungal Drugs Revenues by
Type 2009 and 2013
- Table 3-13: The World Market for Antifungal Drugs Estimated Products
Sales by Geographic Region 2006-2013
- Figure 3-6: The World Market for Antifungal Drugs Estimated Product
Sales by Geographic Region 2006-2013
- Table 3-14: World Antifungal Market Estimated Products Sales by
Infection Type, Sales in Millions, 2009
- Figure 3-7: World Antifungal Market Estimated Distribution of Products
Sales by Infection Type, 2009
- Table 3-15: World Market for Antifungal Drugs Estimated Revenues and
Market Share of Leading Suppliers 2006-2009
- Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of
Leading Suppliers 2006-2009
- Figure 3-9: World Market for Antifungal Drugs Estimated Market Share
of Leading Suppliers, 2009
- Table 3-16: World Market for Antifungal Drugs Estimated Sales of Select
Products 2006-2009
- Figure 3-10: World Market for Antifungal Drugs Estimated Sales of
Select Products 2006-2009
CHAPTER FOUR: ANTIBACTERIAL DRUGS
- Table 4-1: Antibiotics with Difficult Penetration
- Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections
- Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
- Table 4-3: World Population at Risk for Serious Bacterial Infections,
Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
- Figure 4-2: World Population at Risk for Serious Bacterial Infections
Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
- Table 4-4: Currently Available Cephalosporin Antibiotics
(Type, Brand, and Manufacturer)
- Table 4-5: Currently Available Macrolide Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-7: Currently Available Quinolone Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-8: Currently Available Sulfonamide Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-9: Currently Available Tetracycline Antibiotics (Type, Brand, and
Manufacturer)
- Table 4-10: Currently Available Carbopenems (Type, Brand, and
Manufacturer)
- Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type,
Brand, and Manufacturer)
- Table 4-12: The World Market for Antibacterial Drugs 2006-2013
- Figure 4-3: The World Market for Antibacterial Drugs 2006-2013
- Table 4-13: Antibacterial Drug Market by Type 2006-2013
- Figure 4-4: The World Market for Antibacterial Drugs Revenues by
Type 2006-2013
- Figure 4-5: The World Market for Antibacterial Drugs Revenues by
Type 2009 and 2013
- Table 4-14: The World Market for Antibacterial Drugs Estimated
Products Sales by Geographic Region 2006-2013
- Figure 4-6: The World Market for Antibacterial Drugs Estimated Product
Sales by Geographic Region 2006-2013
- Table 4-17: World Antibacterial Market Estimated Products Sales
by Infection Type
- Figure 4-7: World Antibacterial Market Estimated Distribution of Products
Sales by Infection Type, 2009
- Table 4-18: World Market for Antibacterial Drugs Estimated Revenues and
Market Share of Leading Suppliers 2006-2009
- Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of
Leading Suppliers 2006-2009
- Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share
of Leading Suppliers, 2009
- Table 4-19: World Market for Antibacterial Drugs Estimated Sales of
Select Products 2006-2009
- Figure 4-10: World Market for Antibacterial Drugs Estimated Sales of
Top Ten Products 2006-2009
CHAPTER FIVE: ANTIVIRAL DRUGS
- Table 5-1: Host Cell Receptors
- Table 5-2: Estimated World and U.S. Incidence of Viral Infections
- Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
- Table 5-3: Currently Available Nucleoside Reverse Transcriptase Inhibitors
(Type, Brand, and Manufacturer) -
- Table 5-4: Currently Available Combination Nucleoside Reverse
Transcriptase Inhibitors (Type, Brand, and Manufacturer)
- Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase
Inhibitors (Type, Brand, and Manufacturer)
- Table 5-6: Currently Available Non-Nucleoside Reverse Transcriptase
Inhibitors (Type, Brand, and Manufacturer)
- Table 5-7: Currently Available Combination Non-Nucleoside Reverse
Transcriptase Inhibitors (Type, Brand, and Manufacturer)
- Table 5-8: Currently Available DNA Polymerase Inhibitors (Type, Brand,
and Manufacturer)
- Table 5-9: Currently Available Protease Inhibitors (Type, Brand, and
Manufacturer)
- Table 5-10: Currently Available Miscellaneous Antivirals (Type, Brand,
and Manufacturer)
- Table 5-11: The World Market for Antiviral Drugs 2006-2013
- Figure 5-2: The World Market for Antiviral Drugs 2006-2013
- Table 5-12: Antiviral Drug Market by Type 2006-2013
- Figure 5-3: The World Market for Antiviral Drugs Revenues
by Type 2006-2013
- Figure 5-4: The World Market for Antiviral Drugs Revenues by
Type 2009 and 2013
- Table 5-13: The World Market for Antiviral Drugs Estimated Products
Sales by Geographic Region 2006-2013
- Figure 5-5: The World Market for Antiviral Drugs Estimated Product
Sales by Geographic Region 2006-2013
- Table 5-14: World Antiviral Market Estimated Products Sales
by Infection Type
- Figure 5-6: World Antiviral Market Estimated Distribution of Products
Sales by Infection Type, 2009
- Table 5-15: World Market for Antiviral Drugs Estimated Revenues and
Market Share of Leading Suppliers 2006-2009
- Figure 5-7: World Market for Antiviral Drugs Estimated Revenues
of Leading Suppliers 2006-2009
- Figure 5-8: World Market for Antiviral Drugs Estimated Market
Share of Leading Suppliers, 2009
- Table 5-16: World Market for Antiviral Drugs Estimated Sales
of Top Products 2006-2009
- Figure 5-9: World Market for Antiviral Drugs Estimated
Sales of Top Products 2006-2009
CHAPTER SIX: MARKET SUMMARY
- Table 6-1: The Global Market for Anti-Infectives by
ProductSegment, 2006-2013
- Figure 6-1: The World Market for Anti-Infective Drugs 2006-2013
- Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2009
- Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2013
AbstractThe anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them.
This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of treatment:
- Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals)
- Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous)
- Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)
For each category and each subsegment, current market and forecast is provided. The report covers both currently marketed and late stage development products.. Revenues for each segment were generated using dollar sales for each product.
The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. As part of its coverage the report provides: - Overview
- Description of Products on the Market
- Review of Products in Late Stage Development
- Market Estimates and Forecasts
- Competitive Analysis of Leading Providers
- Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia)
- Market Share of Antifungal, Antibacterial and Antiviral Market
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
